Comparative Pharmacology
Head-to-head clinical analysis: GRIS PEG versus VANOBID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GRIS PEG versus VANOBID.
GRIS-PEG vs VANOBID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Griseofulvin binds to and disrupts microtubule function by interfering with the polymerization of tubulin, thereby inhibiting fungal cell mitosis and nucleic acid synthesis.
Vancomycin inhibits cell wall synthesis by binding to the D-alanyl-D-alanine terminus of peptidoglycan precursors, preventing cross-linking.
For tinea capitis and other dermatophyte infections: 500 mg oral daily as a single dose or in divided doses. For more severe infections, up to 1 g daily in divided doses.
500-1000 mg orally every 12 hours or 250 mg every 6 hours.
None Documented
None Documented
Terminal elimination half-life 14-24 hours. With continuous therapy, time to steady-state is ~3-5 days.
Terminal elimination half-life: 8-12 hours in patients with normal renal function; prolonged to 20-40 hours in severe renal impairment (CrCl <30 mL/min), necessitating dose adjustment.
Primarily renal (as glucuronide conjugates): ~80%; fecal/biliary: ~10-15%; unchanged drug <1%.
Renal (unchanged): 30-50% within 24 hours; Biliary/fecal: 15-25% as metabolites; remainder undergoes hepatic metabolism.
Category C
Category C
Antifungal
Antifungal and Corticosteroid Combination